Document Detail

Advances in pemphigus therapy.
MedLine Citation:
PMID:  18506357     Owner:  NLM     Status:  MEDLINE    
The pemphigus variants represent a group of potentially life-threatening autoimmune mucocutaneous blistering diseases. Though systemic corticosteroids have dramatically reduced the rate of disease mortality, current therapeutic options are limited by their toxicity profiles. Advancements in our understanding of the molecular mechanisms involved in the pathogenesis of pemphigus have translated into the development of novel therapies. However, few treatments have been subject to randomized controlled trials to firmly establish therapeutic efficacy. Herein, we focus on the new and emerging therapies in the management of pemphigus.
V Prajapati; P R Mydlarski
Related Documents :
15790317 - Airway gene therapy and cystic fibrosis.
15054087 - Gene and cell-based therapies for heart disease.
19253087 - Evidence-based approach to challenging issues in the management of invasive aspergillosis.
14765017 - Disease recurrence after radical prostatectomy. contemporary diagnostic and therapeutic...
3491527 - Ct of interstitial lung disease: a diagnostic approach.
20951917 - Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel d...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Skin therapy letter     Volume:  13     ISSN:  1201-5989     ISO Abbreviation:  Skin Therapy Lett.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-05-28     Completed Date:  2008-07-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9891441     Medline TA:  Skin Therapy Lett     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  4-7     Citation Subset:  IM    
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / therapeutic use
Glucocorticoids / therapeutic use*
Immunoglobulins, Intravenous / therapeutic use
Immunologic Factors / therapeutic use
Immunosorbents / therapeutic use
Immunosuppressive Agents / therapeutic use
Pemphigus / therapy*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Glucocorticoids; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Immunosorbents; 0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Topical therapy for the management of childhood psoriasis: part I.
Next Document:  Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal ox...